nach oben

Erschienen in:

01.09.2014 | Leitlinien

DGRh-S3-Leitlinie Axiale Spondyloarthritis inklusive Morbus Bechterew und Frühformen

3 Klinische Symptomatik

verfasst von: Dr. U. Kiltz, M. Rudwaleit, J. Sieper, D. Krause, J.-F. Chenot, A. Stallmach, S. Jaresch, U. Oberschelp, E. Schneider, B. Swoboda, H. Böhm, A. Heiligenhaus, U. Pleyer, W.-H. Böhncke, M. Stemmer, J. Braun

Erschienen in: Zeitschrift für Rheumatologie | Sonderheft 2/2014

Einloggen, um Zugang zu erhalten

Auszug

Schlüsselfrage 7: Welche muskuloskelettalen Symptome können bei Patienten mit Spondyloarthritis auftreten und wie sollte das Assessment aussehen (Häufigkeit und welche)? …

Braun J, Sieper J (2007) Ankylosing spondylitis. Lancet 369(9570):1379–1390PubMedCrossRef

Rojas-Vargas M et al (2009) First signs and symptoms of spondyloarthritis – data from an inception cohort with a disease course of two years or less (REGISPONSER-Early). Rheumatology (Oxford) 48(4):404–409

Calin A et al (1977) Clinical history as a screening test for ankylosing spondylitis. JAMA 237(24):2613–2614PubMedCrossRef

Rudwaleit M et al (2006) Inflammatory back pain in ankylosing spondylitis: a reassessment of the clinical history for application as classification and diagnostic criteria. Arthritis Rheum 54(2):569–578PubMedCrossRef

Sieper J et al (2009) New criteria for inflammatory back pain in patients with chronic back pain: a real patient exercise by experts from the Assessment of SpondyloArthritis international Society (ASAS). Ann Rheum Dis 68(6):784–788PubMedCrossRef

Landewe R et al (2009) Physical function in ankylosing spondylitis is independently determined by both disease activity and radiographic damage of the spine. Ann Rheum Dis 68(6):863–867PubMedCrossRef

Machado P et al (2010) Both structural damage and inflammation of the spine contribute to impairment of spinal mobility in patients with ankylosing spondylitis. Ann Rheum Dis 69(8):1465–1470PubMedCrossRef

Ruta S et al (2011) Prevalence of subclinical enthesopathy in patients with spondyloarthropathy: an ultrasound study. J Clin Rheumatol 17(1):18–22PubMedCrossRef

Maksymowych WP et al (2009) Development and validation of the Spondyloarthritis Research Consortium of Canada (SPARCC) enthesitis index. Ann Rheum Dis 68(6):948–953PubMedCrossRef

10.

Heuft-Dorenbosch L et al (2003) Assessment of enthesitis in ankylosing spondylitis. Ann Rheum Dis 62(2):127–132PubMedCentralPubMedCrossRef

11.

Sidiropoulos PI et al (2008) Evidence-based recommendations for the management of ankylosing spondylitis: systematic literature search of the 3E Initiative in Rheumatology involving a broad panel of experts and practising rheumatologists. Rheumatology (Oxford) 47(3):355–361

12.

Karberg K et al (2005) Bone loss is detected more frequently in patients with ankylosing spondylitis with syndesmophytes. J Rheumatol 32(7):1290–1298PubMed

13.

Jun JB et al (2006) Femoral bone mineral density is associated with vertebral fractures in patients with ankylosing spondylitis: a cross-sectional study. J Rheumatol 33(8):1637–1641PubMed

14.

Gratacos J et al (1999) Significant loss of bone mass in patients with early, active ankylosing spondylitis: a followup study. Arthritis Rheum 42(11):2319–2324PubMedCrossRef

15.

Vosse D et al (2009) Ankylosing spondylitis and the risk of fracture: results from a large primary care-based nested case-control study. Ann Rheum Dis 68(12):1839–1842PubMedCrossRef

16.

Montala N et al (2011) Prevalence of vertebral fractures by semiautomated morphometry in patients with ankylosing spondylitis. J Rheumatol 38(5):893–897PubMedCrossRef

17.

Westerveld LA, Verlaan JJ, Oner FC (2009) Spinal fractures in patients with ankylosing spinal disorders: a systematic review of the literature on treatment, neurological status and complications. Eur Spine J 18(2):145–156PubMedCentralPubMedCrossRef

18.

Haywood KL et al (2004) Spinal mobility in ankylosing spondylitis: reliability, validity and responsiveness. Rheumatology (Oxford) 43(6):750–757

19.

Wanders A et al (2005) Association between radiographic damage of the spine and spinal mobility for individual patients with ankylosing spondylitis: can assessment of spinal mobility be a proxy for radiographic evaluation? Ann Rheum Dis 64(7):988–994PubMedCentralPubMedCrossRef

20.

Heuft-Dorenbosch L et al (2004) Measurement of spinal mobility in ankylosing spondylitis: comparison of occiput-to-wall and tragus-to-wall distance. J Rheumatol 31(9):1779–1784PubMed

21.

Deyo RA, Diehr P, Patrick DL (1991) Reproducibility and responsiveness of health status measures. Statistics and strategies for evaluation. Control Clin Trials 12(4 Suppl):142S–158SPubMedCrossRef

22.

Pile KD et al (1991) Clinical assessment of ankylosing spondylitis: a study of observer variation in spinal measurements. Br J Rheumatol 30(1):29–34PubMedCrossRef

23.

Gladman DD et al (2007) International spondyloarthritis interobserver reliability exercise – the INSPIRE study: I. Assessment of spinal measures. J Rheumatol 34(8):1733–1739PubMed

24.

Kennedy LG et al (1995) Ankylosing spondylitis: the correlation between a new metrology score and radiology. Br J Rheumatol 34(8):767–770PubMedCrossRef

25.

Chandran V et al (2007) Relationship between spinal mobility and radiographic damage in ankylosing spondylitis and psoriatic spondylitis: a comparative analysis. J Rheumatol 34(12):2463–2465PubMed

26.

Jenkinson TR et al (1994) Defining spinal mobility in ankylosing spondylitis (AS). The Bath AS Metrology Index. J Rheumatol 21(9):1694–1698PubMed

27.

Calin A et al (1994) A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index. J Rheumatol 21(12):2281–2285PubMed

28.

Garrett S et al (1994) A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol 21(12):2286–2291PubMed

29.

Ruof J, Sangha O, Stucki G (1999) Evaluation of a German version of the Bath Ankylosing Spondylitis Functional Index (BASFI) and Dougados Functional Index (D-FI). Z Rheumatol 58(4):218–225PubMedCrossRef

30.

Boonen A et al (2009) Spinal radiographic changes in ankylosing spondylitis: association with clinical characteristics and functional outcome. J Rheumatol 36(6):1249–1255PubMedCrossRef

31.

Ward MM et al (2005) Risk factors for functional limitations in patients with long-standing ankylosing spondylitis. Arthritis Rheum 53(5):710–717PubMedCentralPubMedCrossRef

32.

Daltroy LH et al (1990) A modification of the Health Assessment Questionnaire for the spondyloarthropathies. J Rheumatol 17(7):946–950PubMed

33.

Doward LC et al (2007) Translation and validation of non-English versions of the Ankylosing Spondylitis Quality of Life (ASQOL) questionnaire. Health Qual Life Outcomes 5:7PubMedCentralPubMedCrossRef

34.

Vander Cruyssen B et al (2007) The epidemiology of ankylosing spondylitis and the commencement of anti-TNF therapy in daily rheumatology practice. Ann Rheum Dis 66(8):1072–1077CrossRef

35.

Brophy S, Calin A (2001) Ankylosing spondylitis: interaction between genes, joints, age at onset, and disease expression. J Rheumatol 28(10):2283–2288PubMed

36.

Rudwaleit M et al (2009) The early disease stage in axial spondylarthritis: results from the German Spondyloarthritis Inception Cohort. Arthritis Rheum 60(3):717–727PubMedCrossRef

37.

Kiltz U et al (2012) Do patients with non-radiographic axial spondylarthritis differ from patients with ankylosing spondylitis? Arthritis Care Res (Hoboken) 64(9):1415–1422CrossRef

38.

Collantes E et al (2007) Disease pattern of spondyloarthropathies in Spain: description of the first national registry (REGISPONSER) extended report. Rheumatology (Oxford) 46(8):1309–1315

39.

Bremander A et al (2011) Population-based estimates of common comorbidities and cardiovascular disease in ankylosing spondylitis. Arthritis Care Res (Hoboken) 63(4):550–556CrossRef

40.

Chorus AM et al (2003) Quality of life and work in patients with rheumatoid arthritis and ankylosing spondylitis of working age. Ann Rheum Dis 62(12):1178–1184PubMedCentralPubMedCrossRef

41.

Zeboulon N, Dougados M, Gossec L (2008) Prevalence and characteristics of uveitis in the spondyloarthropathies: a systematic literature review. Ann Rheum Dis 67(7):955–959PubMedCrossRef

42.

Rosenbaum JT (1992) Acute anterior uveitis and spondyloarthropathies. Rheum Dis Clin North Am 18(1):143–151PubMed

43.

Accorinti M et al (2010) Clinical features and prognosis of HLA B27-associated acute anterior uveitis in an Italian patient population. Ocul Immunol Inflamm 18(2):91–96PubMedCrossRef

44.

Munoz-Fernandez S et al (2003) Sulfasalazine reduces the number of flares of acute anterior uveitis over a one-year period. J Rheumatol 30(6):1277–1279PubMed

45.

Benitez-Del-Castillo JM et al (2000) Sulfasalazine in the prevention of anterior uveitis associated with ankylosing spondylitis. Eye (Lond) 14(Pt 3A):340–343

46.

Braun J et al (2005) Decreased incidence of anterior uveitis in patients with ankylosing spondylitis treated with the anti-tumor necrosis factor agents infliximab and etanercept. Arthritis Rheum 52(8):2447–2451PubMedCrossRef

47.

Sieper J et al (2010) Analysis of uveitis rates across all etanercept ankylosing spondylitis clinical trials. Ann Rheum Dis 69(1):226–229PubMedCrossRef

48.

Rudwaleit M et al (2009) Adalimumab effectively reduces the rate of anterior uveitis flares in patients with active ankylosing spondylitis: results of a prospective open-label study. Ann Rheum Dis 68(5):696–701PubMedCentralPubMedCrossRef

49.

Mielants H et al (1996) Course of gut inflammation in spondylarthropathies and therapeutic consequences. Baillieres Clin Rheumatol 10(1):147–164PubMedCrossRef

50.

Mielants H et al (1995) The evolution of spondyloarthropathies in relation to gut histology. III. Relation between gut and joint. J Rheumatol 22(12):2279–2284PubMed

51.

D’Inca R et al (2009) Articular manifestations in inflammatory bowel disease patients: a prospective study. Dig Liver Dis 41(8):565–569CrossRef

52.

Peeters H et al (2008) Clinical and genetic factors associated with sacroiliitis in Crohn’s disease. J Gastroenterol Hepatol 23(1):132–137PubMed

53.

Vavricka SR et al (2011) Frequency and risk factors for extraintestinal manifestations in the Swiss inflammatory bowel disease cohort. Am J Gastroenterol 106(1):110–119PubMedCrossRef

54.

El Miedany Y et al (2006) The gastrointestinal safety and effect on disease activity of etoricoxib, a selective cox-2 inhibitor in inflammatory bowel diseases. Am J Gastroenterol 101(2):311–317CrossRef

55.

Hoffmann JC et al (2008) Clinical practice guideline on diagnosis and treatment of Crohn’s disease. Z Gastroenterol 46(9):1094–1146PubMedCrossRef

56.

Braun J et al (2007) Differences in the incidence of flares or new onset of inflammatory bowel diseases in patients with ankylosing spondylitis exposed to therapy with anti-tumor necrosis factor alpha agents. Arthritis Rheum 57(4):639–647PubMedCrossRef

57.

Marzo-Ortega H et al (2003) Efficacy of etanercept for treatment of Crohn’s related spondyloarthritis but not colitis. Ann Rheum Dis 62(1):74–76PubMedCentralPubMedCrossRef

58.

Toussirot E et al (2011) Development of inflammatory bowel disease during anti-TNF-alpha therapy for inflammatory rheumatic disease. A nationwide series. Joint Bone Spine

59.

Bergfeldt L et al (1982) Ankylosing spondylitis: an important cause of severe disturbances of the cardiac conduction system. Prevalence among 223 pacemaker-treated men. Am J Med 73(2):187–191PubMedCrossRef

60.

O’Neill TW, Bresnihan B (1992) The heart in ankylosing spondylitis. Ann Rheum Dis 51(6):705–706CrossRef

61.

Sampaio-Barros PD et al (2007) Pulmonary involvement in ankylosing spondylitis. Clin Rheumatol 26(2):225–230PubMedCrossRef

62.

El Maghraoui A et al (2004) Lung findings on thoracic high-resolution computed tomography in patients with ankylosing spondylitis. Correlations with disease duration, clinical findings and pulmonary function testing. Clin Rheumatol 23(2):123–128CrossRef

63.

Souza AS Jr et al (2004) Pulmonary abnormalities in ankylosing spondylitis: inspiratory and expiratory high-resolution CT findings in 17 patients. J Thorac Imaging 19(4):259–263PubMedCrossRef

64.

Gratacos J et al (1997) Secondary amyloidosis in ankylosing spondylitis. A systematic survey of 137 patients using abdominal fat aspiration. J Rheumatol 24(5):912–915PubMed

65.

Peters MJ et al (2004) Cardiovascular risk profile of patients with spondylarthropathies, particularly ankylosing spondylitis and psoriatic arthritis. Semin Arthritis Rheum 34(3):585–592PubMedCrossRef

66.

Heeneman S, Daemen MJ (2007) Cardiovascular risks in spondyloarthritides. Curr Opin Rheumatol 19(4):358–362PubMedCrossRef

67.

Choe JY et al (2008) No differences of carotid intima-media thickness between young patients with ankylosing spondylitis and healthy controls. Joint Bone Spine 75(5):548–553PubMedCrossRef

68.

Gonzalez-Juanatey C et al (2009) The high prevalence of subclinical atherosclerosis in patients with ankylosing spondylitis without clinically evident cardiovascular disease. Medicine (Baltimore) 88(6):358–365

69.

Peters MJ et al (2010) Signs of accelerated preclinical atherosclerosis in patients with ankylosing spondylitis. J Rheumatol 37(1):161–166PubMedCrossRef

70.

Peters MJ et al (2010) Ankylosing spondylitis: a risk factor for myocardial infarction? Ann Rheum Dis 69(3):579–581PubMedCrossRef

71.

Mathieu S et al (2011) Cardiovascular profile in ankylosing spondylitis: a systematic review and meta-analysis. Arthritis Care Res (Hoboken) 63(4):557–563CrossRef

72.

Halm VP van et al (2006) Increased disease activity is associated with a deteriorated lipid profile in patients with ankylosing spondylitis. Ann Rheum Dis 65(11):1473–1477PubMedCentralPubMedCrossRef

73.

Spanakis E et al (2006) Modest but sustained increase of serum high density lipoprotein cholesterol levels in patients with inflammatory arthritides treated with infliximab. J Rheumatol 33(12):2440–2446PubMed

74.

Eijk IC van et al (2009) Improvement of lipid profile is accompanied by atheroprotective alterations in high-density lipoprotein composition upon tumor necrosis factor blockade: a prospective cohort study in ankylosing spondylitis. Arthritis Rheum 60(5):1324–1330PubMedCrossRef

75.

Eijk IC van et al (2009) Microvascular function is impaired in ankylosing spondylitis and improves after tumour necrosis factor alpha blockade. Ann Rheum Dis 68(3):362–366PubMedCrossRef

76.

Peters MJ et al (2010) EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis. Ann Rheum Dis 69(2):325–331PubMedCrossRef

77.

Tubergen A van et al (2002) Assessment of fatigue in patients with ankylosing spondylitis: a psychometric analysis. Arthritis Rheum 47(1):8–16PubMedCrossRef

78.

Jones SD et al (1996) Fatigue in ankylosing spondylitis: its prevalence and relationship to disease activity, sleep, and other factors. J Rheumatol 23(3):487–490PubMed

79.

Dagfinrud H et al (2005) Fatigue in patients with ankylosing spondylitis: a comparison with the general population and associations with clinical and self-reported measures. Arthritis Rheum 53(1):5–11PubMedCrossRef

80.

Zochling J, Braun J (2009) Mortality in rheumatoid arthritis and ankylosing spondylitis. Clin Exp Rheumatol 27(4 Suppl 55):S127–S130PubMed

81.

Brown WM, Doll R (1965) Mortality from cancer and other causes after radiotherapy for ankylosing spondylitis. Br Med J 2(5474):1327–1332PubMedCentralPubMedCrossRef

82.

Wick RR et al (2008) Increased risk of myeloid leukaemia in patients with ankylosing spondylitis following treatment with radium-224. Rheumatology (Oxford) 47(6):855–859

83.

Bakland G, Gran JT, Nossent JC (2011) Increased mortality in ankylosing spondylitis is related to disease activity. Ann Rheum Dis 70(11):1921–1925PubMedCrossRef

84.

Zink A, Minden K (2010) Entzündlich rheumatische Erkrankungen, Heft 49, In: R.-K.I. Berlin (Hrsg). Gesundheitsberichterstattung des Bundes

Titel: DGRh-S3-Leitlinie Axiale Spondyloarthritis inklusive Morbus Bechterew und Frühformen
3 Klinische Symptomatik
verfasst von: Dr. U. Kiltz
M. Rudwaleit
J. Sieper
D. Krause
J.-F. Chenot
A. Stallmach
S. Jaresch
U. Oberschelp
E. Schneider
B. Swoboda
H. Böhm
A. Heiligenhaus
U. Pleyer
W.-H. Böhncke
M. Stemmer
J. Braun
Publikationsdatum: 01.09.2014
Verlag: Springer Berlin Heidelberg
Erschienen in: Zeitschrift für Rheumatologie / Ausgabe Sonderheft 2/2014
Print ISSN: 0340-1855
Elektronische ISSN: 1435-1250
DOI: https://doi.org/10.1007/s00393-014-1428-6

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

25.04.2024 | Hypotonie | Nachrichten

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

DGRh-S3-Leitlinie Axiale Spondyloarthritis inklusive Morbus Bechterew und Frühformen

3 Klinische Symptomatik

Auszug

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Update Innere Medizin

Springer Medizin

Auszug

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Sonderheft 2/2014